Intrinsic Therapeutics
2 known investors
Barricaid develops a bone-anchored implant designed to reduce reherniation and reoperation in patients undergoing discectomy for large annular defects. The device is marketed to physicians and patients with lumbar disc herniation.
Medical Devices
Investors · 2
In the news
- Intrinsic Therapeutics Announces Initial Release of Its Next Generation Barricaid Narrow Anchor Device Designed to Reduce Reherniation After Back Surgeryprnewswire.com · 2026
- Intrinsic Therapeutics - 2025 Company Profile, Funding & Competitors - Tracxntracxn.com · 2021
- Intrinsic Therapeutics raises $52m for Barricaid annulus seal - MassDevicemassdevice.com · 2019
- Intrinsic Therapeutics Completes $52m Financing to Fuel Commercial Efforts in the United States to Benefit Lumbar Discectomy Patientsprnewswire.com · 2019
- Intrinsic Therapeutics Completes $52M Financing - FinSMEsfinsmes.com · 2019
- Intrinsic Therapeutics lands $11.6M in new funding for treatment of herniated lumbar discs -orthostreams.com · 2012